Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of PLEKHS1 promoter mutation in preoperative thyroid nodule samples.

Cancer cytopathology - 1 May 2026

Azad Sarah, Graham Timothy E, Levy Shiri, Velanzuela-Sheker Evana, Bimston David, Ferenczi Andrea, Chen Yang, Alshalalfa Mohammed, Hao Yangyang, Klopper Joshua P, Kloos Richard T, Kotwal Anupam

Abstract excerpt

Indeterminate thyroid nodules carry a wide range of malignancy prevalence, necessitating incorporation of molecular testing to guide management. Molecular test results help guide prognosis to a certain extent, but additional prognostic factors need to be identified. Limited data have linked PLEKHS1 promoter (PLEKHS1p) mutations with higher aggressiveness of thyroid cancer. Hence, we aimed to evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carrier Proteins

Share to Intracellular Signaling Peptides and Proteins

Share to Prognosis

Share to Promoter Regions, Genetic

Share to Thyroid Neoplasms

Share to Thyroid Nodule

Source

Open in PubMed Open full text

Identifiers

PMID: 42080574
DOI: 10.1002/cncy.70103
PMCID: PMC13138096

Genes

PLEKHS1
GSC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of PLEKHS1 promoter mutation in preoperative thyroid nodule samples.PMID 42080574Read ↗

PLEKHS1 Over-Expression is Associated with Metastases and Poor Outcomes in Papillary Thyroid CarcinomaSemantic proximity Read ↗

Preoperative molecular testing in thyroid nodules with Bethesda VI cytology: Clinical experience and review of the literature.Semantic proximity Read ↗

Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules.Semantic proximity Read ↗

The Diagnostic Value of BRAF V600E Gene Detection Combined with DNA Ploidy Analysis in Thyroid Cancer.Semantic proximity Read ↗

Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next-generation sequencing of thyroid FNA samples?Semantic proximity Read ↗

Small Multi-Gene DNA Panel Can Aid in Reducing the Surgical Resection Rate and Predicting the Malignancy Risk of Thyroid Nodules.Semantic proximity Read ↗

Molecular profiling of thyroid nodules on cytologic samples: Findings from an Italian multi-institutional cohort.Semantic proximity Read ↗

Combined Afirma Genomic Sequencing Classifier and TERT promoter mutation detection in molecular assessment of Bethesda III-VI thyroid nodules.Semantic proximity Read ↗

Next Generation Sequence-Based Targeted Somatic Mutation Analysis in Thyroid Nodules with Pathologically Diagnosed as Indeterminate CytologySemantic proximity Read ↗

Discovery and validation of PARP4 methylation in distinguishing thyroid cancer from benign nodule.Semantic proximity Read ↗

A mutation panel comprising BRAFV600E, NRASQ61R, and NRASQ61H replicated retrospective histopathological examination findings in differentiating benign goitre from malignant papillary thyroid cancer in a cohort of Malaysian patients.Semantic proximity Read ↗

Risk of malignancy in cytologically indeterminate thyroid nodules harboring thyroid stimulating hormone receptor mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.